CIVIL PENALTY FUNDS USE BY MANUFACTURERS FOR CORRECTIVE ACTIONS PROPOSED BY HIMA; LEGISLATIVE PROPOSAL ALSO WOULD REVISE SURVEILLANCE, TRACKING RULES
This article was originally published in The Gray Sheet
Device manufacturers subject to civil penalties would be allowed to use the money to implement corrective actions rather than paying it to the U.S. Treasury under a Health Industry Manufacturers Association proposal for revamping FDA device legislation.
You may also be interested in...
Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.